当前位置: 首页 >> 检索结果
1741. In large acute ischemic stroke, adding endovascular thrombectomy to medical therapy improved function at 90 d.
Sarraj A, Hassan AE, Abraham MG, et al; SELECT2 Investigators. Trial of endovascular thrombectomy for large ischemic strokes. N Engl J Med. 2023;388:1259-1271. 36762865.
1743. In symptomatic PAH, adding sotatercept to stable background therapy improved 6-min walk distance at 24 wk.
Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388:1478-1490. 36877098.
1744. In hypertension not treated with medications, renal denervation vs. sham reduced daytime ambulatory SBP at 2 mo.
Azizi M, Saxena M, Wang Y, et al; RADIANCE II Investigators and Collaborators. Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II randomized clinical trial. JAMA. 2023;329:651-661. 36853250.
1745. Diagnostic Strategies for the Assessment of Suspected Stable Coronary Artery Disease : A Systematic Review and Meta-analysis.
作者: Andrea Zito.;Mattia Galli.;Giuseppe Biondi-Zoccai.;Antonio Abbate.;Pamela S Douglas.;Giuseppe Princi.;Domenico D'Amario.;Cristina Aurigemma.;Enrico Romagnoli.;Carlo Trani.;Francesco Burzotta.
来源: Ann Intern Med. 2023年176卷6期817-826页
There is uncertainty about which diagnostic strategy for detecting coronary artery disease (CAD) provides better outcomes.
1747. Effects of Implementation of a Supervised Walking Program in Veterans Affairs Hospitals : A Stepped-Wedge, Cluster Randomized Trial.
作者: Susan N Hastings.;Karen M Stechuchak.;Ashley Choate.;Courtney Harold Van Houtven.;Kelli D Allen.;Virginia Wang.;Cathleen Colón-Emeric.;George L Jackson.;Teresa M Damush.;Cassie Meyer.;Caitlin B Kappler.;Helen Hoenig.;Nina Sperber.;Cynthia J Coffman.
来源: Ann Intern Med. 2023年176卷6期743-750页
In trials, hospital walking programs have been shown to improve functional ability after discharge, but little evidence exists about their effectiveness under routine practice conditions.
1748. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
作者: Kristina L Bajema.;Kristin Berry.;Elani Streja.;Nallakkandi Rajeevan.;Yuli Li.;Pradeep Mutalik.;Lei Yan.;Francesca Cunningham.;Denise M Hynes.;Mazhgan Rowneki.;Amy Bohnert.;Edward J Boyko.;Theodore J Iwashyna.;Matthew L Maciejewski.;Thomas F Osborne.;Elizabeth M Viglianti.;Mihaela Aslan.;Grant D Huang.;George N Ioannou.
来源: Ann Intern Med. 2023年176卷6期807-816页
Information about the effectiveness of oral antivirals in preventing short- and long-term COVID-19-related outcomes in the setting of Omicron variant transmission and COVID-19 vaccination is limited.
1749. In type 2 MI, the T2-risk score predicted death or MI at 1 y.
Taggart C, Monterrubio-Gómez K, Roos A, et al. Improving risk stratification for patients with type 2 myocardial infarction. J Am Coll Cardiol. 2023;81:156-168. 36631210.
1751. Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States.
作者: George Goshua.;Cecelia Calhoun.;Satoko Ito.;Lyndon P James.;Andrea Luviano.;Lakshmanan Krishnamurti.;Ankur Pandya.
来源: Ann Intern Med. 2023年176卷6期779-787页
Gene therapy is a potential cure for sickle cell disease (SCD). Conventional cost-effectiveness analysis (CEA) does not capture the effects of treatments on disparities in SCD, but distributional CEA (DCEA) uses equity weights to incorporate these considerations.
1754. Comparison of Hospital Outcomes for Patients Treated by Allopathic Versus Osteopathic Hospitalists : An Observational Study.
作者: Atsushi Miyawaki.;Anupam B Jena.;Nate Gross.;Yusuke Tsugawa.
来源: Ann Intern Med. 2023年176卷6期798-806页
The United States has 2 types of degree programs that educate physicians: allopathic and osteopathic medical schools.
1755. Association of Low-Dose Colchicine With Incidence of Knee and Hip Replacements : Exploratory Analyses From a Randomized, Controlled, Double-Blind Trial.
作者: Michelle W J Heijman.;Aernoud T L Fiolet.;Arend Mosterd.;Jan G P Tijssen.;Bart J F van den Bemt.;Astrid Schut.;John W Eikelboom.;Peter L Thompson.;Cornelia H M van den Ende.;Stefan M Nidorf.;Calin D Popa.;Jan H Cornel.
来源: Ann Intern Med. 2023年176卷6期737-742页
Osteoarthritis is a major contributor to pain and disability worldwide. Given that inflammation plays an important role in the development of osteoarthritis, anti-inflammatory drugs may slow disease progression.
1757. Mental Health and Health-Related Quality of Life After Firearm Injury: A Preliminary Descriptive Study.
作者: Sydney C Timmer-Murillo.;Sarah J H Melin.;Carissa W Tomas.;Timothy J Geier.;Amber Brandolino.;Andrew T Schramm.;Christine L Larson.;Terri A deRoon-Cassini.
来源: Ann Intern Med. 2023年176卷7期1010-1012页 1758. Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study.
作者: Wayne A Ray.;Cecilia P Chung.;C Michael Stein.;Walter Smalley.;Eli Zimmerman.;William D Dupont.;Adriana M Hung.;James R Daugherty.;Alyson L Dickson.;Katherine T Murray.
来源: Ann Intern Med. 2023年176卷6期769-778页
Amiodarone, the most effective antiarrhythmic drug in atrial fibrillation, inhibits apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk for bleeding.
1759. Population-Wide Screening for Chronic Kidney Disease : A Cost-Effectiveness Analysis.
作者: Marika M Cusick.;Rebecca L Tisdale.;Glenn M Chertow.;Douglas K Owens.;Jeremy D Goldhaber-Fiebert.
来源: Ann Intern Med. 2023年176卷6期788-797页
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have the potential to alter the natural history of chronic kidney disease (CKD), and they should be included in cost-effectiveness analyses of screening for CKD.
|